JP2005179246A - Allergic hypersensitivity inhibitor - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain a novel drug or drink which ameliorates many symptoms observed in allergic hypersensitivity. <P>SOLUTION: The subject allergic hypersensitivity inhibitor contains molasses as an active ingredient. This inhibitor contains honey originated from Chinese milk vetches (Astragalus sinicus L.). <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

  The present invention relates to an inhibitor of allergic hypersensitivity that has become hypersensitive by exposure to allergens.

  Allergic diseases caused by various allergens such as pollen, nitrogen oxides, and house dust have become one of the national health problems as it is said that more than 20% of the Japanese population is currently affected. Yes. In particular, the symptoms at the onset are so-called nasal congestion, increased nasal discharge and tears, inflammation of the eyes and nasal mucosa, and are very troublesome to interfere with daily life. It has been broken.

  Some patients suffering from this allergic disease have increased immediate and delayed responsiveness to allergens by repeated exposure to allergens, and also exhibit excessive responses to nonspecific stimuli. It has been known. Such symptoms are called allergic hypersensitivity.

  This allergic hypersensitivity is caused not only by repeatedly exposed allergens but also by other allergens. It is virtually impossible to avoid all of these allergens completely. Therefore, as a countermeasure against allergic hypersensitivity, the fact is that the administration of a substance that suppresses this allergic reaction must be relied upon.

  As such substances, antihistamines such as chlorpheniramine maleate and carbinoxamine maleate are widely used. However, they have the function of suppressing the immune response of the living body, and also have side effects such as sleepiness when taken. Therefore, a safer antiallergic hypersensitivity substance derived from natural ingredients has been awaited.

  The inventors of the present invention have used a model animal exhibiting symptoms of allergic hypersensitivity, and as a result of trying to search for an effective substance for the same symptoms, found the effect of alleviating the same symptoms on honey and completed the present invention. did.

  That is, the present invention relates to an allergic hypersensitivity inhibitor containing honey as an active ingredient. In particular, the present invention relates to an allergic hypersensitivity inhibitor containing honey derived from astragalus grass or deproteinized honey as an active ingredient.

  The present invention can relieve symptoms of allergic hypersensitivity without side effects by ingesting honey, a food with established safety.

  As the honey that can be used in the present invention, those derived from various honeys can be used. However, the use of honey obtained by beekeeping mainly using the flowers of astragalus plants, particularly the flowers of astragalus grass (Astragalus sinicus L.). preferable. In addition, use of honey that has been subjected to a simple purification treatment such as deproteinization is also suitable.

  In fact, it is impossible to strictly limit the plants that serve as nectar for beekeeping. Therefore, even if beekeeping is performed using astragalus grass as the main nectar source, the contamination of nectar from other plants is completely prevented. I can't do that. However, even in such a case, if the composition contains honey collected by beekeeping using astragalus plants as the main nectar and the nectar derived from the astragalus plants is substantially the main ingredient, they are allergic. It can be used as an allergic hypersensitivity inhibitor according to the present invention.

  The amount of honey to be administered or taken should be determined individually based on the age, sex, severity of symptoms, etc. of the allergic hypersensitivity patient to be applied, and the dosage form and method of administration. .

  In addition to the collected honey, the honey may be sterilized, dried, or purified by, for example, a method known to those skilled in the art, such as deproteinization.

  The inhibitor of the present invention can be used, for example, as a pharmaceutical or food form. In the case of pharmaceuticals, such compositions are particularly suitable for oral administration. When the composition of the present invention is clinically used as a pharmaceutical composition, various preparations can be prepared by adding pharmaceutically acceptable additives according to the administration form. As the pharmaceutically acceptable additive, various additives generally used in the pharmaceutical field can be used. For example, gelatin, lactose, sucrose, titanium oxide, starch, crystalline cellulose, hydroxypropylmethylcellulose, carboxymethylcellulose , Corn starch, microcrystalline wax, white petrolatum, magnesium aluminate metasilicate, anhydrous calcium phosphate, citric acid, trisodium citrate, hydroxypropylcellulose, sorbitol, sorbitan fatty acid ester, polysorbate, sucrose fatty acid ester, polyoxyethylene hydrogenated castor oil , Polyvinylpyrrolidone, magnesium stearate, light anhydrous silicic acid, talc, vegetable oil, benzyl alcohol, gum arabic, propylene glycol, polyalkylene glycol Lumpur, cyclodextrin or hydroxypropyl cyclodextrin and the like. Examples of the dosage form formulated as a mixture with these additives include solid preparations such as tablets, capsules, granules and the like; or liquid preparations such as syrups, which are usually used in the pharmaceutical field. It can be prepared by the method. Moreover, the inhibitor of this invention can also be arbitrarily mix | blended with various foodstuffs, for example, solid, liquid, sol, a gel-like foodstuff, etc. The blending can be performed by any production method known in the art, for example, a solid food such as caramel, biscuit or chocolate; a liquid food such as beverage; a retort food such as azuki bean as a raw material, or It can be easily blended separately. In particular, from the viewpoint of simple use in daily life, it is desirable to be in the form of food.

  Moreover, said inhibitor can also be used for the use as a food additive which suppresses allergic hypersensitivity. When used as the food additive, using methods well known to those skilled in the art, for example, various excipients such as dextrin, corn starch, and lactose, and auxiliary materials such as emulsifiers, and the like derived from the astragalus grass of the present invention. It can be produced by mixing or encapsulating honey or deproteinized honey. Moreover, you may add a preservative, a fragrance | flavor, etc. if desired.

  The invention will now be described in more detail by way of non-limiting examples.

  A liquid allergic hypersensitivity inhibitor was prepared by diluting 20 mL of honey (Akitaya Honten) collected from Chinese astragalus with 20 mL of water.

20 mL of deproteinized honey (Akitaya Honten) was diluted twice with 20 mL of water to prepare a liquid allergic hypersensitivity inhibitor containing deproteinized honey.
<Test example>
1) Construction of allergic nasal hypersensitivity model animal i) Preparation of cedar pollen extract containing aluminum hydroxide (Al (OH) ₃ ) 10 g of cedar pollen was added to 100 mL of phosphate buffered saline (PBS), After suspending at 4 ° C. for 48 hours, the supernatant was collected by centrifugation at 3000 rpm for 15 minutes, and diluted with PBS so that the protein concentration was 200 μg / mL.

A 200 mg / mL aqueous solution of Al (OH) ₃ was prepared, 9 mg of sodium chloride was added to 1 mL of this aqueous solution, and 1 mL of the above diluted cedar pollen extract was added dropwise with stirring in ice, and Al (OH) ₃ was added. A cedar pollen extract containing was prepared.
ii) Sensitization of guinea pigs with cedar pollen The cedar pollen extract prepared in i) was dropped into the nasal cavity of the guinea pig twice a day at a dose of 3 μL and administered continuously for 7 days. Furthermore, cedar pollen was inhaled into one nose at a rate of 3 mg once a week from the final sensitization to elicit a reaction. This inhalation can cause allergic rhinitis in guinea pigs. Furthermore, when repeated reaction induction by cedar pollen is repeated, the rise of nasal resistance increases after the 4th reaction induction from 30 minutes to 2 hours (immediate) and from 4 to 6 hours (late) after induction. Observed with good reproducibility. In addition, even when histamine was administered to the nasal cavity, the concentration-dependent increase in nasal resistance was observed, and the non-sensitized group showed reactivity from a low concentration of 1000 times or more. A guinea pig showing such a biphasic allergic reaction was used as a model animal for allergic nasal hypersensitivity.
iii) Effect of the allergic hypersensitivity inhibitor of the present invention on model animals Group A, which gives only regular diet to guinea pigs not sensitized with cedar pollen, and suppresses regular diet and allergic hypersensitivity to guinea pigs prepared in ii) Group B, ii) giving 4 mL / kg body weight / times / day of water in place of the agent, giving 4 mL / kg body weight / times / day of the allergic hypersensitivity inhibitor prepared in Example 1 to the guinea pigs prepared in ii) Prepare a total of 4 groups, 4 groups / group D, giving 4 mL / kg body weight / times / day of the allergic hypersensitivity inhibitor prepared in Example 2 to the guinea pigs prepared in Group C, ii) for 16 consecutive days Each bait and water or allergic hypersensitivity inhibitor was orally administered.

  One hour after the last administration of water or the allergic hypersensitivity inhibitor, Koirotriene D4 (LTD4) was administered nasally, and changes in nasal resistance were monitored. The result is shown in FIG.

  In group A (marked with ○) that does not show allergic symptoms, nasal resistance does not change even if the dose of LTD4 is increased, whereas in group B (marked with ●) that shows allergic symptoms with cedar pollen, the dose of LTD4 is increased. In dependence, nasal resistance increased. On the other hand, group C (□ mark) in which the allergic hypersensitivity inhibitor prepared in Example 1 was administered to such guinea pigs for 16 days, and group D (■ in which allergic hypersensitivity inhibitor prepared in Example 2 was administered). (Symbols) showed almost the same results as those of Group A, and the administration of the allergic hypersensitivity inhibitor of the present invention was observed to suppress the development of allergic nasal hypersensitivity by the administration of LTD4.

  On the other hand, the number of immediate sneezes observed by sensitizing cedar pollen under the same conditions is not significantly suppressed even when the allergic hypersensitivity inhibitor prepared in Examples 1 and 2 is administered in advance. It was not recognized (FIG. 2). Therefore, it is presumed that the allergic hypersensitivity inhibitor of the present invention exhibits an effect by a mechanism different from the action on IgE.

FIG. 1 is a graph showing the inhibitory effect of the present invention on allergic nasal hypersensitivity. FIG. 2 is a graph showing the effect of the present invention on the number of sneezing confirmed after induction of an allergic reaction with cedar pollen.

Claims (5)

  An allergic hypersensitivity inhibitor containing honey as an active ingredient.   2. The allergic hypersensitivity inhibitor according to claim 1, wherein the honey is derived from astragalus sinicus L ..   The allergic hypersensitivity inhibitor according to claim 1 or 2, wherein the honey is deproteinized honey.   The allergic hypersensitivity inhibitor according to any one of claims 1 to 3, wherein the allergic hypersensitivity is allergic nasal hypersensitivity.   The allergic hypersensitivity inhibitor according to any one of claims 1 to 4, which is in the form of food.

Images